LuciBeda (Bedaquiline)

Inquire / Price
  • Model Number:
    RL612025122801
  • Brand Name:
    LuciBeda
  • Origin:
    Generic drug,Laos
  • Small Orders:
    Small batches also available
  • Tags:
Inquire Now Link

Poster
  • Details
  • Description
  • Packaging Size
    188t/Bottle
  • Strength
    100mg
  • Compositon
    Bedaquiline
  • Treatment
    Multidrug Resistant Pulmonary Tuberculosis
  • Form
    Tablet
  • Brand
    LuciBeda
  • Quantity Unit
    100mg*188t/Box
  • Manufacturer
    Lucius Pharmaceuticals (Lao) Co.,Ltd

About Bedaquiline

Bedaquiline is used in combination with other medicines to treat pulmonary tuberculosis of the lungs caused by Mycobacterium tuberculosis that is resistant to other medicines (eg, rifampin, isoniazid). Bedaquiline prevents the growth of tuberculosis in the body.

Multidrug Resistant Pulmonary Tuberculosis

Diarylquinoline antimycobacterial indicated as part of combination therapy for pulmonary tuberculosis (TB) due to Mycobacterium tuberculosis resistant to at least rifampin and isoniazid

Only use in combination with at least 3 other drugs to which the patient’s TB isolate has been shown to be susceptible in vitro; if in vitro testing results are unavailable, may be initiated in combination with at least 4 other drugs to which the patient’s TB isolate is likely to be susceptible

Weeks 1-2: 400 mg PO once daily for 2 weeks, THEN

Weeks 3-24: 200 mg PO 3 times/week with at least 48 hr between doses

If treatment is considered necessary beyond 24 weeks, may continue at 200 mg PO 3 times/week

Dosage Modifications

Renal impairment

  • Mild-to-moderate: No dosage adjustment required
  • Severe or end-stage renal disease requiring hemodialysis or peritoneal dialysis: Use with caution; if used, monitor for adverse reactions of bedaquiline

Hepatic impairment

  • Mild or moderate (Child-Pugh A or B): No dosage adjustment required
  • Severe (Child-Pugh C): Not studied; use only if benefits outweigh risks

Dosing Considerations

Limitations of use

  • Do not use for treatment of
    • Latent infection due to Mycobacterium tuberculosis
    • Drug-sensitive tuberculosis
    • Extra-pulmonary tuberculosis
    • Infections caused by nontuberculous mycobacteria

Required testing before administration

  • Susceptibility information for background regimen against M tuberculosis isolate if possible
  • ECG
  • Serum potassium, calcium, and magnesium concentrations
  • Liver enzymes

Link

Poster

Top